The development of the UK National Institute of Health and Care Excellence evidence-based clinical guidelines on motor neurone disease

Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
David OliverChristopher McDermott

Abstract

The care of people with motor neuron disease/amyotrophic lateral sclerosis is often complex and involves a wide multidisciplinary team approach. The National Institute for Health and Care Excellence (NICE) in the UK has produced an evidence based guideline for the management of patients. This has made recommendations, based on clear evidence or consensus discussion. The evidence is often limited and areas for further research are suggested.

References

Aug 23, 2003·Journal of Neurology, Neurosurgery, and Psychiatry·B J TraynorO Hardiman
Apr 15, 2006·Journal of Neurology, Neurosurgery, and Psychiatry·A ChiòUNKNOWN PARALS
Sep 12, 2006·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Heino HugelCarolyn A Young
Apr 26, 2008·BMJ : British Medical Journal·Gordon H GuyattUNKNOWN GRADE Working Group
Jan 16, 2009·Muscle & Nerve·Carlayne E JacksonUNKNOWN Muscle Study Group
Mar 25, 2009·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Tracy L Peters, Mary Kay Floeter
Jan 7, 2011·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Mary R O'BrienJohn Douglas Mitchell
May 13, 2011·The Cochrane Database of Systematic Reviews·Carolyn A YoungNicky Pih
Sep 15, 2011·European Journal of Neurology : the Official Journal of the European Federation of Neurological Societies· Markus Weber
Apr 20, 2012·Health Expectations : an International Journal of Public Participation in Health Care and Health Policy·Robin A RayAnnette F Street
May 31, 2012·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Tomi AridegbeChristopher J McDermott
Mar 8, 2013·Patient Preference and Adherence·Anne HogdenMatthew C Kiernan
Jun 21, 2013·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Sharon AbrahamsThomas H Bak
Aug 16, 2013·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration·Johannes DorstAlbert C Ludolph
Sep 12, 2013·Nephron. Clinical Practice·Indranil DasguptaUNKNOWN NICE Hyperphosphataemia Guideline Development Group
Sep 24, 2013·Palliative Medicine·Susan K BaxterChristopher J McDermott
Jan 1, 2015·Journal of Neurology, Neurosurgery, and Psychiatry·James RooneyOrla Hardiman
Apr 11, 2015·Journal of Neurology·Marwa ElaminOrla Hardiman

❮ Previous
Next ❯

Citations

Oct 6, 2017·The Cochrane Database of Systematic Reviews·Aleksandar RadunovicNaveed Mustfa
Nov 21, 2018·Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration
Jul 10, 2019·Journal of Evaluation in Clinical Practice·Camille PaynterAdam P Vogel
Dec 5, 2019·Revista da Escola de Enfermagem da U S P·Tatiana YonekuraArmando Antonio De Negri Filho
Sep 16, 2017·Current Opinion in Neurology·Marianne de Visser, David J Oliver
Jan 11, 2017·The Cochrane Database of Systematic Reviews·Louisa NgMary Galea
Dec 23, 2020·International Journal of Language & Communication Disorders·Richard Cave, Steven Bloch

❮ Previous
Next ❯

Related Concepts

Related Feeds

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

© 2022 Meta ULC. All rights reserved